On April 30, 2026, Eli Lilly and Company submitted an SEC 8-K filing — categorized as a Q1 2026 sales and earnings report — that referenced retatrutide by name. The filing, publicly available through the SEC's EDGAR full-text search system, marks another formal acknowledgment of retatrutide as a pipeline asset under active development within Lilly's commercial and financial disclosures. For patients and clinicians following the obesity medicine landscape, the appearance of retatrutide in a quarterly earnings document signals that Lilly continues to treat this triple agonist as a material component of its near-term growth story.
Retatrutide — commonly referred to as reta in patient communities — is a once-weekly subcutaneous injection that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This tri-receptor mechanism, sometimes called "triple G" in online patient forums, distinguishes retatrutide from every currently approved obesity medication. By adding glucagon receptor activity to the GLP-1/GIP combination already seen in tirzepatide, retatrutide drives additional energy expenditure on top of appetite suppression — a pharmacological profile that appears to translate into meaningfully greater weight loss in clinical trials.
It is worth noting that as of April 2026, no New Drug Application (NDA) has been filed with the FDA, and no approval timeline has been publicly confirmed by Lilly. The Q1 2026 earnings filing does not change that regulatory reality, but it does confirm that retatrutide remains a named priority within Lilly's corporate reporting framework.
Lilly's obesity and cardiometabolic portfolio has become one of the most closely watched segments in all of biopharma. With tirzepatide (Zepbound) already generating substantial revenue, the question for investors and patients alike is how retatrutide fits into the next phase of Lilly's growth. The Q1 2026 8-K filing's reference to retatrutide in the context of sales and earnings reporting suggests the company is actively framing the drug as a future revenue contributor — not a distant research project.
The clinical data supporting that commercial optimism is substantial. In December 2025, Lilly released top-line results from TRIUMPH-4, the Phase 3 obesity trial of retatrutide. The headline figure — 28.7% mean weight loss at the 12mg dose over 68 weeks — is the highest ever recorded in a Phase 3 obesity trial. To put that in context, consider how retatrutide compares to the two agents that redefined obesity medicine over the past several years:
| Drug | Mechanism | Pivotal Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 | 68 weeks | 28.7% |
Phase 2 data, published in the New England Journal of Medicine in 2023, laid the foundation for this trajectory. In that trial (n=338, 48 weeks), participants receiving 8mg retatrutide achieved mean weight loss of approximately 22.8%, with 100% of participants in that dose group reaching at least a 5% reduction in body weight. At the 12mg dose, mean weight loss reached approximately 24.2%, with 48% of participants losing 25% or more of their body weight. These figures were unprecedented at the time of publication and helped position retatrutide as a potential category-defining therapy.
Beyond body weight, Phase 2 data also demonstrated meaningful improvements in cardiometabolic markers. At 24 weeks, fasting triglycerides declined by approximately 34% at the 12mg dose compared to just 3.1% with placebo. Total cholesterol fell approximately 17.3% at 12mg. LDL cholesterol decreased approximately 15.6–16.9% in the 8mg groups. Quality of life scores, measured by the SF-36v2, improved across all active dose groups at week 48. For patients living with obesity-related conditions such as dyslipidemia or hypertension, these downstream effects on cardiometabolic risk factors may prove as clinically meaningful as the weight loss itself — a point likely to feature prominently in any future NDA submission and payer negotiations.
Reading SEC filings for clinical drug development timelines requires care. An 8-K is a material event disclosure, and while the inclusion of retatrutide in a Q1 earnings report confirms its pipeline prominence, it does not provide a specific regulatory milestone date. As of April 2026, Lilly has not filed an NDA for retatrutide with the FDA, and the peer-reviewed publication of the TRIUMPH-4 Phase 3 data remains pending.
What the Q1 2026 filing does confirm is that Lilly is treating retatrutide as financially relevant in the near term. Companies do not typically highlight pipeline compounds in earnings reports unless those assets are expected to transition from development to commercial reality within a foreseeable planning horizon. Combined with the TRIUMPH-4 press release data released in December 2025, the picture that emerges is of a drug that has cleared its most important efficacy hurdle — demonstrating record-breaking weight loss in a Phase 3 setting — and is moving through the remaining regulatory and publication steps.
Safety data from TRIUMPH-4 deserve careful attention as well. Discontinuation rates at the 12mg dose were 18.2%, compared to 4.0% with placebo. Dysesthesia — an abnormal skin sensation — occurred in 20.9% of participants at the 12mg dose versus 0.7% with placebo. These figures are consistent with the direction signaled in Phase 2, where hyperesthesia and dysesthesia were reported in approximately 12.9–14.3% of participants at higher doses. Nausea, diarrhea, and vomiting remain the most common adverse events across dose groups, consistent with the class-wide GI profile of GLP-1–based therapies. Managing the titration schedule carefully — in TRIUMPH-4, participants escalated from 2mg through 4mg, 6mg, and 9mg before reaching the 12mg maintenance dose — appears central to tolerability optimization.
For patients who have already achieved meaningful results on semaglutide or tirzepatide but want to understand what a next-generation triple agonist might offer, the trajectory from Phase 2 through TRIUMPH-4 represents the strongest clinical case for any obesity drug to date. The question now is regulatory timing — and that answer will come from future Lilly disclosures, not earnings filings alone.
If retatrutide is on your radar, the most informed step available right now is to join the waitlist at glp3md.com. The waitlist is designed to keep patients current on regulatory developments, clinical data, and access updates as they emerge. Joining the waitlist does not guarantee access to retatrutide, any treatment, or a prescription — retatrutide is not FDA-approved, and no promises about medication availability can or should be made. What it does provide is a structured way to stay ahead of one of the most significant developments in obesity medicine in a generation.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.